RT Journal Article
T1 Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice
A1 del Carmen Alamo, Ma
A1 Ochenduszko, Sebastian
A1 Crespo, Guillermo
A1 Corral, Monica
A1 Oramas, Juana
A1 Sancho, Pilar
A1 Medina, Javier
A1 Garicano, Fernando
A1 Lopez, Pedro
A1 Campos Balea, Begona
A1 Rodriguez Garzotto, Analia
A1 Munoz-Couselo, Eva
K1 vemurafenib
K1 cobimetinib
K1 BRAF
K1 metastatic melanoma
K1 durable response
K1 clinical practice
K1 Combination
K1 Mortality
K1 Outcomes
K1 Therapy
K1 Cohort
K1 V600e
AB Background: The combination of BRAF and MEK inhibitors delays the onset of resistance and provides more sustained and dramatic responses in comparison with a BRAF inhibitor in monotherapy. The objective of the study was to evaluate the effectiveness of the combination therapy with vemurafenib/cobimetinib in terms of durability, and to describe differential characteristics in patients associated to durable responses in real-world settings.Patients and Methods: Retrospective, observational, cross-sectional, multicenter study involving 41 patients with advanced melanoma harboring a BRAF(v600) mutation who initiated a combination therapy with vemurafenib/cobimetinib between May 2018 and March 2019. Participants were differentiated regarding the durability of the response: durable (complete response, CR, or a partial response, PR, for at least 12 months) and non-durable (stable disease, SD, progressive disease, PD, or CR/PR
PB Dove medical press ltd
SN 1178-6930
YR 2021
FD 2021-01-01
LK https://hdl.handle.net/10668/26599
UL https://hdl.handle.net/10668/26599
LA en
DS RISalud
RD Apr 5, 2025